Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 91

Results For "WHO"

2723 News Found

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Clinical Trials | March 23, 2024

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes


USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
News | March 23, 2024

USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

Oscotec has successfully completed phase 2 study in patients with chronic ITP last year


Zydus receives tentative approval from USFDA for Letermovir Tablets
Drug Approval | March 23, 2024

Zydus receives tentative approval from USFDA for Letermovir Tablets

Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)


IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion
News | March 21, 2024

IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion

Pharma Solutions operates 10 research and development and/or production sites globally


Bristol Myers Squibb completes acquisition of Karuna Therapeutics
News | March 21, 2024

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia


AstraZeneca buys biopharmaceutical company Fusion
News | March 20, 2024

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer


AstraZeneca to acquire Amolyt Pharma
News | March 18, 2024

AstraZeneca to acquire Amolyt Pharma

Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition


Bayer and Aignostics to collaborate on next generation precision oncology
News | March 16, 2024

Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development